Roche builds evidence for Evrysdi’s benefits in younger SMA patientsRoche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing Share XRoche builds evidence for Evrysdi’s benefits in younger SMA patientshttps://pharmaphorum.com/news/roche-builds-evidence-for-evrysdis-benefits-younger-sma-patients/
Novartis cleared to restart trials of new Zolgensma delivery routeThe FDA has relaxed a clinical hold on clinical trials of Novartis’ intrathecal formulation of spinal muscular atrophy Share XNovartis cleared to restart trials of new Zolgensma delivery routehttps://pharmaphorum.com/news/novartis-cleared-to-restart-trials-of-new-zolgensma-delivery-route/
NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient groupNICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, Share XNICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient grouphttps://pharmaphorum.com/news/nice-no-to-roches-risdiplam-for-sma-not-unexpected-says-patient-group/
Novartis says £1.8m Zolgensma is model for gene therapy pricingNovartis has said its gene therapy pricing model, involving a steep one-off payment, could be a template for Share XNovartis says £1.8m Zolgensma is model for gene therapy pricinghttps://pharmaphorum.com/news/novartis-e1-9m-zolgensma-is/
Ex-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOAfter more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down Share XEx-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOhttps://pharmaphorum.com/news/ex-taris-ceo-tony-kingsley-claims-tenure-as-scholar-rocks-new-ceo/
FDA delays decision on Roche’s SMA drug to review extra dataThe FDA has extended its review of Roche’s spinal muscular atrophy (SMA) drug risdiplam after the pharma submitted Share XFDA delays decision on Roche’s SMA drug to review extra datahttps://pharmaphorum.com/news/fda-delays-decision-on-roches-sma-drug-to-review-extra-data/
FDA lets off Novartis after gene therapy data rowNovartis is off the hook following the FDA’s review of data manipulation in the filing of its hugely Share XFDA lets off Novartis after gene therapy data rowhttps://pharmaphorum.com/news/fda-lets-off-novartis-after-gene-therapy-data-row/
Novartis closes on EU approval for SMA gene therapy ZolgensmaNovartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in Share XNovartis closes on EU approval for SMA gene therapy Zolgensmahttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-sma-gene-therapy-zolgensma/
Novartis publishes long-term data from SMA gene therapyNovartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting Share XNovartis publishes long-term data from SMA gene therapyhttps://pharmaphorum.com/news/novartis-publishes-long-term-data-from-sma-gene-therapy/
